1-chloro-4-hydrazinophthalazine hydrochloride | 6145-55-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 1-chloro-4-hydrazinophthalazine hydrochloride
• 英文别名: 4-chloro-1-hydrazinophthalazine hydrochloride；4-hydrazino-1-chlorophthalazine hydrochloride；(4-chloro-phthalazin-1-yl)-hydrazine; hydrochloride；(4-Chlor-phthalazin-1-yl)-hydrazin; Hydrochlorid；(4-chlorophthalazin-1-yl)hydrazine;hydrochloride
• CAS: 6145-55-7
• 化学式: C₈H₇ClN₄*ClH
• 分子量: 231.084
• InChiKey: CILIDGFBNLYLMH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.99
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.8
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-chloro-4-hydrazinophthalazine hydrochloride 在 sodium hydride 、 三乙胺 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 28.33h， 生成 3-Ethyl-6-(pyridin-2-ylmethoxy)-[1,2,4]triazolo[3,4-a]phthalazine
  参考文献：
  名称：

  3-Phenyl-6-(2-pyridyl)methyloxy-1,2,4-triazolo[3,4-a]phthalazines and Analogues:  High-Affinity γ-Aminobutyric Acid-A Benzodiazepine Receptor Ligands with α2, α3, and α5-Subtype Binding Selectivity over α1

  摘要：

  Studies with our screening lead 5 and the literature compound 6 led to the identification of 6-benzyloxy-3-(4-methoxy)phenyl-1,2,4-triazolo[3,4-a]phthalazine 8 as a ligand with binding selectivity for the gamma-aminobutyric acid-A (GABA-A) alpha3- and alpha5-containing receptor subtypes over the GABA-A alpha1 subtype (K-i: alpha2 = 850 nM, alpha3 = 170 nM, alpha5 = 72 nM, alpha1 = 1400 nM). Early optimization studies identified the close analogue 10 (Ki: alpha2 = 16 nM, alpha3 = 41 nM, alpha5 = 38 nM, alpha1 = 280 nM) as a suitable lead for further study. High-affinity ligands were identified by replacing the 6-benzyloxy group of compound 10 with 2-pyridylmethoxy (compound 29), but binding selectivity was not enhanced (K-i: alpha2 = 1.7 nM, alpha3 = 0.71 nM, alpha5 = 0.33 nM, alpha1 = 2.7 nM). Furthermore, on evaluation in xenopus oocytes,(22) 29 was discovered to be a weak to moderate inverse agonist at all four receptor subtypes (alpha1, -7%; alpha2, -5%; alpha3, -16%; alpha5, -5%). Replacement of the 3-phenyl group of 29 with alternatives led to reduced affinity, and smaller 3-substituents led to reduced efficacy. Methyl substitution of the benzo-fused ring of 29 at the 7-, 8-, and 10-positions resulted in increased efficacy although selectivity was abolished. Increased efficacy and retention of selectivity for alpha3 over alpha1 was achieved with the 7,8,9,10-tetrahydro-(7,10-ethano)-phthalazine 62. Compound 62 is currently one of the most binding selective GABA-A alpha3-benzodiazepine-site partial agonists known, and although its selectivity is limited, its good pharmacokinetic profile in the rat (33% oral bioavailability after a 3 mg/kg dose, reaching a peak plasma concentration of 179 ng/mL; half-life of I h) made it a useful pharmacological tool to explore the effect of a GABA-A alpha2/alpha3 agonist in vivo.

  DOI：

  10.1021/jm031020p
• 作为产物：
  描述：

  1,4-二氯酞嗪 在 一水合肼 作用下， 生成 1-chloro-4-hydrazinophthalazine hydrochloride
  参考文献：
  名称：

  酞嗪和哒嗪系列的肼衍生物

  摘要：

  描述了酞嗪和哒嗪的肼基衍生物，其药理学兴趣已在其他地方报道。基本类型的化学修饰涉及杂环或芳香环上的取代，吡啶环取代芳香核，最后改变肼残基。

  DOI：

  10.1002/hlca.19510340122

文献信息

• Substituted triazolo-pyridazine derivatives as ligands for GABA receptors
  申请人：Merck Sharp & Dohme Limited

  公开号：US06255305B1

  公开（公告）日：2001-07-03

  Substituted triazolo-pyridazine derivative compounds represented by wherein the variables are disclosed herein are selective ligands for GABA-A receptors, particularly for the &agr;2 and/or &agr;3 subunits.

  这些变量如上所披露的取代三唑吡啶衍生物化合物是GABA-A受体的选择性配体，特别是对于α2和/或α3亚基。
• [EN] TRIAZOLO-PYRIDAZINE COMPOUNDS AND DERIVATIVES THEREOF USEFUL IN THE TREATMENT OF NEUROPATHIC PAIN<br/>[FR] COMPOSES DE TRIAZOLO-PYRIDAZINE ET LEURS DERIVES, DESTINES AU TRAITEMENT DE LA DOULEUR NEUROPATHIQUE
  申请人：MERCK & CO INC

  公开号：WO2005041971A1

  公开（公告）日：2005-05-12

  The present invention is directed to a method of use of triazolo-pyridazine compounds in the treatment of neuropathic pain. The present invention is also directed to the use of triazolo-pyridazine compounds in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorders, and panic, as well as in the treatment of pain, Parkinson’s disease, cognitive dysfunction, epilepsy, circadian rhythm and sleep disorders - such as shift-work induced sleep disorder and jet-lag, drug addiction, drug abuse, drug withdrawal and other diseases. The present invention is also directed to novel triazolo-pyridazine compounds that selectively bind to α2δ-1 subunit of Ca channels.

  本发明涉及一种在治疗神经病性疼痛中使用三唑吡啶化合物的方法。本发明还涉及在治疗精神和情绪障碍，如精神分裂症、焦虑、抑郁、躁郁症和恐慌，以及在治疗疼痛、帕金森病、认知功能障碍、癫痫、昼夜节律和睡眠障碍（如倒班引起的睡眠障碍和时差反应）、药物成瘾、药物滥用、药物戒断和其他疾病中使用三唑吡啶化合物的方法。本发明还涉及选择性结合到Ca通道α2δ-1亚基的新型三唑吡啶化合物。
• Combination therapy
  申请人：——

  公开号：US20040102360A1

  公开（公告）日：2004-05-27

  The present invention relates to methods of treating cancer using a combination of at least two Akt inhibitors or a compound which is an inhibitor of Akt and an inhibitor of a protein kinase, which methods comprise administering to a mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound(s) which are inhibitors of Akt and compound(s) which are inhibitors of protein kinases. The invention also relates to methods of preparing such compositions.

  本发明涉及使用至少两种Akt抑制剂的组合或一种同时是Akt抑制剂和蛋白激酶抑制剂的化合物来治疗癌症的方法，该方法包括向哺乳动物施用来自以下组合中选择的至少两种治疗剂的量，该组合包括Akt抑制剂和蛋白激酶抑制剂。该发明还涉及制备这种组合物的方法。
• Therapeutically active 1,2,4-triazolo&lsqb;4.,3-B&rsqb; pyridazine derivatives as ligands for GABA receptors
  申请人：Merck Sharp & Dohme Ltd.

  公开号：US06313125B1

  公开（公告）日：2001-11-06

  1,2,4-triazolo[4,3-b]pyridazine derivatives are ligands for GABAA receptors useful in the treatment of disorders of dementing illnesses.

  1,2,4-三唑[4,3-b]吡啶嗪衍生物是GABAA受体的配体，对治疗痴呆疾病的疗效有用。
• Reactions of methyl 2-(benzyloxycarbonyl)amino-3-dimethylaminopropenoate and related compounds with hydrazines. Regiospecific synthesis of 1-substituted-4-amino-substituted-1<i>H</i>-pyrazol-5-(2<i>H</i>)-ones
  作者：Lucija Jukić Soršak、Gorazd Soršak、Renata Toplak、David Bevk、Jurij Svete、Branko Stanovnik

  DOI：10.1002/jhet.5570430511

  日期：2006.9

  In this paper the regiospecific transformations of methyl 2-(benzyloxycarbonyl)amino-3-dimethylaminopropenoate (1) with hydrazine, alkyl-, aryl- and heteroaryl-substituted hydrazines via the corresponding hydrazones 12-16 into pyrazoles 17-25 are described. Heteroaryl-substitued hydrazones 13-16 afforded by oxidation with bromine or lead tetraacetate the corresponding substituted (1,2,4-triazolo[4

  在本文中，描述了2-（苄氧基羰基）氨基-3-二甲基氨基丙烯酸（1）与肼，烷基，芳基和杂芳基取代的肼通过相应的12-16的区域特异性转化为吡唑17-25。杂芳基取代的腙13-16通过氧化用溴或四乙酸铅的相应的取代的（1,2,4-三唑并[4,3得到b ]哒嗪-3-基）甘氨酸盐27-30。2-（2,2-二取代-1-乙烯基）氨基-3-二甲基氨基丙烯酸烷基酯31-33与肼一起生成2- [2,2-（二取代）乙烯基]氨基-3-杂芳基肼基丙酸烷基酯40-48和2-烷基2，3-双（（杂）芳基肼基）丙酸酯51-55。